Search research articles
Contact Us
Filters
Showing results (121-130 of 221) with videos related to
Page
of 23
Sort By:
Future Oncology (London, England)
|
October 8, 2020
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
Anup Patel, Alain Ravaud, Robert J Motzer, et al.
European Urology
|
April 27, 2021
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
Michiel S van der Heijden, Yohann Loriot, Ignacio Durán, et al.
Bulletin Du Cancer
|
January 7, 2004
[Refining the French system of cost assessment for oncology patients following chemotherapy]
Christine Lévy-Piedbois, Laurent Borella, Philippe Bergerot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
Sylvie Negrier, David Perol, Christine Menetrier-Caux, et al.
JMIR Cancer
|
July 31, 2025
Practical Approaches to Patient-Centered Care in Europe: Mixed Methods Study Developing a Conceptual Framework for Comprehensive Cancer Care Networks
Emily Hickmann, Peggy Richter, Hannes Schlieter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 12, 2017
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, et al.
European Urology
|
September 20, 2011
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01)
Stéphane Culine, Aude Fléchon, Aline Guillot, et al.
Journal of Geriatric Oncology
|
April 18, 2016
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort
Magali Rouyer, Annie Fourrier-Réglat, Denis Smith, et al.
European Urology
|
November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Grant D Stewart, Michael Aitchison, Axel Bex, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 3, 2010
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
Dorothy A White, Philippe Camus, Masahiro Endo, et al.
Page
of 23
Search research articles
Search
Showing results (121-130 of 221) with videos related to
Sort By:
Page
of 23
Future Oncology (London, England)
|
October 8, 2020
Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting
Anup Patel, Alain Ravaud, Robert J Motzer, et al.
European Urology
|
April 27, 2021
Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial
Michiel S van der Heijden, Yohann Loriot, Ignacio Durán, et al.
Bulletin Du Cancer
|
January 7, 2004
[Refining the French system of cost assessment for oncology patients following chemotherapy]
Christine Lévy-Piedbois, Laurent Borella, Philippe Bergerot, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2004
Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6--from the Groupe Francais d'Immunotherapie
Sylvie Negrier, David Perol, Christine Menetrier-Caux, et al.
JMIR Cancer
|
July 31, 2025
Practical Approaches to Patient-Centered Care in Europe: Mixed Methods Study Developing a Conceptual Framework for Comprehensive Cancer Care Networks
Emily Hickmann, Peggy Richter, Hannes Schlieter, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
February 12, 2017
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, et al.
European Urology
|
September 20, 2011
Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01)
Stéphane Culine, Aude Fléchon, Aline Guillot, et al.
Journal of Geriatric Oncology
|
April 18, 2016
Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort
Magali Rouyer, Annie Fourrier-Réglat, Denis Smith, et al.
European Urology
|
November 6, 2016
Cytoreductive Nephrectomy in the Tyrosine Kinase Inhibitor Era: A Question That May Never Be Answered
Grant D Stewart, Michael Aitchison, Axel Bex, et al.
American Journal of Respiratory and Critical Care Medicine
|
March 3, 2010
Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma
Dorothy A White, Philippe Camus, Masahiro Endo, et al.
Page
of 23